-
Teva to acquire MicroDose for up to $165 million
JERUSALEM — Teva Pharmaceutical Industries will spend up to $165 million to buy a company developing a drug to prevent viral respiratory infections.
Teva said it would acquire MicroDose Therapeutx for $40 million, plus up to $125 million in milestone payments and sales milestones and royalties from its lead product, MDT-637, an inhaled treatment for respiratory syncytial virus, or RSV.
-
Perrigo to acquire Fera's ophthalmic portfolio for up to $129 million
ALLEGAN, Mich. — Perrigo Co. will pay up to $129 million to buy Fera Pharmaceuticals' portfolio of ophthalmic products, Perrigo said Monday.
Perrigo said the acquisition from Locust Valley, N.Y.-based Fera included an upfront payment of $93 million and milestone payments of about $36 million. The products include generic ophthalmic sterile ointments and solutions and generated sales of more than $30 million in 2012.